Volume 1 Issue 1
Thibaut Kritter*, Marco Rossi, Thierry Colin, Francois H Cornelis, Egesta Loci, Lorenzo Bello, Clair Poignard and Olivier Saut
Purpose: To identify radiomic based biomarkers able to stratify on progression free survival patients presenting with gliomas.
Material and methods: Clinical, genetic and MR imaging features of 90 patients presenting lower grade gliomas (WHO grade II and III) were used in this study. An indicator of heterogeneity was identified accounting for spatial distribution of the tumor. Interesting features correlated with PFS were recorded and several machine learning strategies were compared to stratify patients into short or long PFS classes.
Results: MET-PET features appear to be strongly linked to PFS. Our method gives a good classification of fast or slow recurrence in 79% of the cases. This classification is more accurate than what is currently obtained with grade or IDH1 status and the combination of two.
Conclusion: Our method seems effective in patient's stratification to better predict clinical behavior. It constitutes a proof of concept of a tool which could have a role on the clinical evaluation of the risk of recurrence of gliomas.
Cite this Article: Kritter T, Rossi M, Colin T, Cornelis FH, Bello L, et al. Radiomic Biomarkers Helps to Better Predict Progression Free Survival of Gliomas. Int J Neurooncol Brain Tumor. 2017;1(1): 014-020.
Published: 27 December 2017
Research Article: Retrospective observational Clinical Study on Relapsed Malignant Gliomas Treated with Electro-Hyperthermia
Giammaria Fiorentini*, Donatella Sarti, Carlo Milandri, Patrizia Dentico, Andrea Mambrini and Stefano Guadagni
Aim: to evaluate the efficacy and tolerability of electro-hyperthermia (ET) for the treatment of relapsed malignant glioma.
Methods: this was a retrospective observational clinical study. Patients were included in the study if they had >18 years, informed consent signed, histological diagnosis of malignant glioma, failure of previous temozolamide-based chemotherapy and radiotherapy, indication for treatment with ET.
Hyperthermia was performed with short radiofrequency waves of 13.56 MHz using a capacitive coupling technique keeping the skin surface at 26 °C. The applied power ranged between 40-150 Watts and the calculated average equivalent temperature in the tumors was above 40 °C for more than 90% of the treatment duration (20-60 minutes gradually).
Results: 24 consecutive patients were enrolled in the study, 19 (79%) had glioblastoma multiforme (GBM) 13 were of grade 1-3 and 6 of grade 4, 5 (21%) astrocitoma.
Tumor response analysis two months after ET showed 2 (8%) complete remission (astrocytomas) and 5 (21%) partial remission (2 astrocitoma, and 3 glioblastomas), with a response rate of 29%. The median duration of response was 16 months (range 6-120).
The median survival of whole study population was 19.5 months (range 2-156), 55% survival rate at 1 year, and 15 % at two years. We observed 3 long survivors at 156, 60, 62 months in atrocitomas.
Conclusions: ET appears to have promising efficacy in adults with relapsed malignant glioma.
Cite this Article: Fiorentini G, Sarti D, Milandri C, Dentico P, Mambrini A, et al. Retrospective observational Clinical Study on Relapsed Malignant Gliomas Treated with Electro-Hyperthermia. Int J Neurooncol Brain Tumor. 2017;1(1): 009-013.
Published: 05 October 2017
Neurotol, a R&D product from Venus Medicine Research Centre in glass bottle for IV infusion in case of trauma, brain injury, neurological surgeries and in management of ICP. One of the major challenge associated with these indications is neurotoxic side effects resulting in sequalaes which turn out be more or equally serious complications even after the trauma is cured. Neurotol offers enhanced safety and efficacy over market competitor products in case of glycerol based neurotherapeutics in a clinical set up. The formulation of Neurotol contains mainly 3 ingredients viz. Mannitol, glycerol and a chemical vector RD011.
Cite this Article: Manu C. Safety a Major Concern with Neurotherpeutic in Traumatic Brain Injury. Int J Neurooncol Brain Tumor. 2017;1(1): 001-008.
Published: 14 September 2017
Authors submit all Proposals and manuscripts via Electronic Form!